147 related articles for article (PubMed ID: 30907047)
1. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
Truong K; Kwan YL; Nigro L; Huseincehajic A; Trotman J
Intern Med J; 2019 Sep; 49(9):1092-1098. PubMed ID: 30907047
[TBL] [Abstract][Full Text] [Related]
2. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
Glasziou PP
Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
[TBL] [Abstract][Full Text] [Related]
3. Financial costs associated with monopolies on biologic medicines in Australia.
Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
[TBL] [Abstract][Full Text] [Related]
4. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
5. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
6. Economic benefits of investigational drug services at an academic institution.
LaFleur J; Tyler LS; Sharma RR
Am J Health Syst Pharm; 2004 Jan; 61(1):27-32. PubMed ID: 14725117
[TBL] [Abstract][Full Text] [Related]
7. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
8. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
9. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
10. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
11. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
12. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
13. What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.
Harris A; Li JJ; Yong K
Pharmacoeconomics; 2016 Apr; 34(4):393-402. PubMed ID: 26610347
[TBL] [Abstract][Full Text] [Related]
14. The financial impact of investigational drug services.
Rogers SD; Lampasona V; Buchanan EC
Top Hosp Pharm Manage; 1994 Apr; 14(1):60-6. PubMed ID: 10133561
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).
Liniker E; Harrison M; Weaver JM; Agrawal N; Chhabra A; Kingshott V; Bailey S; Eisen TG; Corrie PG
Br J Cancer; 2013 Oct; 109(8):2051-7. PubMed ID: 24064969
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of drug cost reduction resulting from the free supply of investigational drugs].
Corvaisier S; Ferry S; Rochefort F
Therapie; 2003; 58(4):353-60. PubMed ID: 14679675
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
Friedberg M; Saffran B; Stinson TJ; Nelson W; Bennett CL
JAMA; 1999 Oct; 282(15):1453-7. PubMed ID: 10535436
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Economic Value of Pharmacy Resident Participation in an Investigational Drug Service.
Brown JN; Gordon SE; Tillman F; Jacob S; Britnell SR
J Pharm Pract; 2021 Feb; 34(1):23-27. PubMed ID: 31232150
[TBL] [Abstract][Full Text] [Related]
19. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
20. Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.
Nipp RD; Lee H; Gorton E; Lichtenstein M; Kuchukhidze S; Park E; Chabner BA; Moy B
Oncologist; 2019 Aug; 24(8):1048-1055. PubMed ID: 30988039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
